{
    "doi": "https://doi.org/10.1182/blood.V116.21.1483.1483",
    "article_title": "Targeting Histone Deacetylase 6 (HDAC6) as a Novel Approach to Overcome T-Cell Anergy. ",
    "article_date": "November 19, 2010",
    "session_type": "Granulocytes, Monocytes and Macrophages: Poster I",
    "abstract_text": "Abstract 1483 The anti-inflammatory molecules IL-10 and STAT3 are major hurdles in our efforts to harness effective anti-tumor immunity 1 . Previously, we have unveiled a role for histone deacetylase 11 (HDAC11) as a negative regulator of IL-10 gene transcriptional activity in antigen-presenting cells (APCs) 2 . In an effort to better characterize the epigenetic influences upon IL-10, we screened other HDACs and found that over-expression of HDAC6 in the macrophage cell line RAW264.7 was able to transcriptionally upregulate IL-10 in response to LPS. Next, using lentiviral vectors encoding shRNA for HDAC6, we generated stable knockdown clones of HDAC6 (HDAC6KD). In contrast to HDAC6 overexpression, HDAC6KD cells produced less IL-10 both at the mRNA and protein levels. Further analysis of HDAC6KD clones revealed elevated expression of the co-stimulatory molecule B7.2. Functionally, LPS-stimulated HDAC6KD cells were better able to activate anti-HA (hemagglutinin-influenza) transgenic CD4 + T cells to produce IL-2 and IFN-\u03b3. More relevant to the tumor setting, anti-HA CD4 + anergic T cells isolated from animals bearing HA-expressing A20 B-cell lymphoma regained their ability to produce IL-2 and IFN-\u03b3 when cultured in vitro with HDAC6KD cells in the presence of cognate HA-antigen. These same T-cells remained anergic when cultured with control APCs displaying normal levels of HDAC6. Mechanistically, we have found that APCs lacking HDAC6 display a significant abrogation of STAT3 activation in response to LPS stimulation. Given the demonstration that HDACs, other than HDAC6, can regulate STAT3 activity 3 , we are actively investigating whether the effect we have observed is a result of direct HDAC6-STAT3 interaction or a diminished autocrine signaling through IL-10. Taken together, through abrogation of two well-known tolerogenic mechanisms in APCs, IL-10 and STAT3, HDAC6 inhibition represents an attractive therapeutic approach to overcome tumor-induced T-cell anergy and tip the balance towards effective anti-lymphoma immunity. 1. Cheng F., et al. Immunity 2003 Sep;19(3):425-36. 2. Villagra A., et al. Nat Immunol. 2009 Jan;10(1):92-100. 3. Yuan Z., et al. Science . 2005 Jan 14;307(5707):269-73. Disclosures: No relevant conflicts of interest to declare.",
    "topics": [
        "anergy",
        "histone deacetylase 6",
        "t-lymphocytes",
        "interleukin-10",
        "stat3 protein",
        "atrial premature complexes",
        "neoplasms",
        "aldesleukin",
        "lymphoma",
        "molecule"
    ],
    "author_names": [
        "Fengdong Cheng",
        "Hongwei Wang",
        "Karrune Woan",
        "Jennifer Rock-Klotz",
        "Zi Wang",
        "Oscar Merino",
        "Ajay Gill",
        "Danay Marante",
        "Lianet Vazquez",
        "Edward Seto",
        "Javier Pinilla-Ibarz, MD",
        "Eduardo M. Sotomayor, MD",
        "Alejandro Villagra"
    ],
    "author_dict_list": [
        {
            "author_name": "Fengdong Cheng",
            "author_affiliations": [
                "Malignant Hematology, H. Lee Moffitt Cancer Ctr. & Rsch. Inst., Tampa, FL, USA, "
            ],
            "author_rank": 1,
            "first_author": 1,
            "last_author": 0
        },
        {
            "author_name": "Hongwei Wang",
            "author_affiliations": [
                "Malignant Hematology, H. Lee Moffitt Cancer Ctr. & Rsch. Inst., Tampa, FL, USA, "
            ],
            "author_rank": 2,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Karrune Woan",
            "author_affiliations": [
                "Malignant Hematology, H. Lee Moffitt Cancer Ctr. & Rsch. Inst., Tampa, FL, USA, "
            ],
            "author_rank": 3,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Jennifer Rock-Klotz",
            "author_affiliations": [
                "Malignant Hematology, H. Lee Moffitt Cancer Ctr. & Rsch. Inst., Tampa, FL, USA, "
            ],
            "author_rank": 4,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Zi Wang",
            "author_affiliations": [
                "Malignant Hematology, H. Lee Moffitt Cancer Ctr. & Rsch. Inst., Tampa, FL, USA, "
            ],
            "author_rank": 5,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Oscar Merino",
            "author_affiliations": [
                "Malignant Hematology, H. Lee Moffitt Cancer Ctr. & Rsch. Inst., Tampa, FL, USA, "
            ],
            "author_rank": 6,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Ajay Gill",
            "author_affiliations": [
                "Malignant Hematology, H. Lee Moffitt Cancer Ctr. & Rsch. Inst., Tampa, FL, USA, "
            ],
            "author_rank": 7,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Danay Marante",
            "author_affiliations": [
                "Malignant Hematology, H. Lee Moffitt Cancer Ctr. & Rsch. Inst., Tampa, FL, USA, "
            ],
            "author_rank": 8,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Lianet Vazquez",
            "author_affiliations": [
                "Malignant Hematology, H. Lee Moffitt Cancer Ctr. & Rsch. Inst., Tampa, FL, USA, "
            ],
            "author_rank": 9,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Edward Seto",
            "author_affiliations": [
                "Molecular Oncology, H. Lee Moffitt Cancer Ctr. & Rsch. Inst., Tampa, FL, USA"
            ],
            "author_rank": 10,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Javier Pinilla-Ibarz, MD",
            "author_affiliations": [
                "Malignant Hematology, H. Lee Moffitt Cancer Ctr. & Rsch. Inst., Tampa, FL, USA, "
            ],
            "author_rank": 11,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Eduardo M. Sotomayor, MD",
            "author_affiliations": [
                "Malignant Hematology, H. Lee Moffitt Cancer Ctr. & Rsch. Inst., Tampa, FL, USA, "
            ],
            "author_rank": 12,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Alejandro Villagra",
            "author_affiliations": [
                "Malignant Hematology, H. Lee Moffitt Cancer Ctr. & Rsch. Inst., Tampa, FL, USA, "
            ],
            "author_rank": 13,
            "first_author": 0,
            "last_author": 1
        }
    ],
    "datetime_abstract_obtained": "2022-05-15T15:35:36",
    "is_scraped": "1"
}